FocalTherics, formerly known as EDAP TMS S.A. (FOCL), a medical technology company, announced Tuesday that it has entered into an agreement with MellingMedical, an SBA-verified Service-Disabled Veteran-Owned Small Business, to expand access to the Focal One Robotic High-Intensity Focused Ultrasound (HIFU) system for veterans with prostate cancer.
The company plans to expand the availability of Focal One across federal healthcare providers, making the prostate treatment technology accessible to veterans and active-duty military personnel throughout the U.S. Department of Veterans Affairs (VA) and Department of Defense healthcare systems.
Prostate cancer care has been a key area of federal focus in recent years, as veterans are diagnosed with prostate cancer at nearly twice the rate of the general population, and the disease accounts for approximately 30% of cancer diagnoses among men in the Veterans Health Administration.
Through MellingMedical's VA Federal Supply Schedule, the agreement is expected to provide access to incision-free, radiation-free robotic focal therapy as a treatment option across the veteran healthcare system.
Chris Melling, Founder and Chief Executive Officer of MellingMedical, said, "This non-invasive treatment approach offers patients the possibility of maintaining their quality of life while effectively treating their condition."
FOCL is currently trading at $4.71, down 0.72%.
For more such biotech stock news, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.